Please use this identifier to cite or link to this item:
Title: Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response.
Austin Authors: Sud, S;O'Callaghan, C ;Jonker, C;Karapetis, C;Price, T;Tebbutt, N ;Shapiro, J;Van Hazel, G;Pavlakis, N;Gibbs, P;Jeffrey, M;Siu, L;Gill, S;Wong, R ;Jonker, D;Tu, D;Goodwin, R
Affiliation: Royal Melbourne Hospital, Melbourne, Victoria, Australia
Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
ncic Clinical Trials Group, Queen's University, Kingston, ON, Canada
Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada
Flinders University and Flinders Medical Centre, Flinders Centre for Innovation in Cancer, Bedford Park, SA
The Queen Elizabeth and University of Adelaide, Adelaide, SA
Austin Health, Heidelberg, Victoria, Australia
Department of Medical Oncology, Monash University, Melbourne, VIC
University of Western Australia, Perth, WA
Royal North Shore Hospital, Northern Clinical School, University of Sydney, St. Leonards, NSW
Oncology Service, Christchurch Hospital, Christchurch, N.Z
University of British Columbia, BC Cancer, Vancouver, BC
CancerCare Manitoba, Winnipeg, MB
Issue Date: 2018
Date: 2018
Publication information: Current oncology (Toronto, Ont.) 2018; 25(6): e516-e526
Abstract: Adrenergic receptor stimulation is involved in the development of hypertension (htn) and has been implicated in cancer progression and dissemination of metastases in various tumours, including colon cancer. Adrenergic antagonists such as beta-blockers (bbs) demonstrate inhibition of invasion and migration in colon cancer cell lines and have been associated with decreased mortality in colorectal cancer (crc). We examined the association of baseline htn and bb use with overall (os) and progression-free survival (pfs) in patients with pretreated, chemotherapy refractory, metastatic crc (mcrc). We also examined baseline htn as a predictor of cetuximab efficacy. Using data from the Canadian Cancer Trials Group co.17 study [cetuximab vs. best supportive care (bsc)], we coded baseline htn and use of anti-htn medications, including bbs, for 572 patients. The chi-square test was used to assess the associations between those variables and baseline characteristics. Cox regression models were used for univariate and multivariate analyses of os and pfs by htn diagnosis and bb use. Baseline htn, bb use, and anti-htn medication use were not found to be prognostic for improved os. Baseline htn and bb use were not significant predictors of cetuximab benefit. In chemorefractory mcrc, neither baseline htn nor bb use is a significant prognostic factor. Baseline htn and bb use are not predictive of cetuximab benefit. Further investigation to determine whether baseline htn or bb use have a similarly insignificant impact on prognosis in patients receiving earlier lines of treatment remains warranted.
DOI: 10.3747/co.25.4069
Journal: Current oncology (Toronto, Ont.)
PubMed URL: 30607118
Type: Journal Article
Subjects: Colorectal cancer
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 7, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.